NC
VTYX

nVerses Capital’s Ventyx Biosciences VTYX Stock Holding History

nVerses Capital’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-8,600
Closed -$18.7K – 882
2024
Q3 		$18.7K Buy
8,600
+4,900
+132% +$11.3K 0.01% 816
2024
Q2 		$8.55K Buy
3,700
+2,800
+311% +$11.6K 0.01% 919
2024
Q1 		$4.95K Buy
+900
New +$4.12K 0.01% 587

Other funds holding VTYX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

nVerses Capital's VTYX Position: Q4 2024 in Review

nVerses Capital sold out of Ventyx Biosciences (VTYX) in Q4 2024, closing a stake of 8,600 shares — an estimated $18.7K sold.

nVerses Capital first reported a position in VTYX in Q1 2024 and held it in 3 quarters. The position peaked at $18.7K in Q3 2024. 124 funds tracked by Wall St. Rank hold VTYX as of Q4 2024.

  • nVerses Capital reported no remaining Ventyx Biosciences position as of Q4 2024 after selling out during the quarter.
  • nVerses Capital sold 8,600 Ventyx Biosciences shares in Q4 2024, an estimated $18.7K.
  • nVerses Capital first reported a position in Ventyx Biosciences in Q1 2024 and held it in 3 quarters.
  • nVerses Capital's Ventyx Biosciences position peaked at $18.7K in Q3 2024.
  • 124 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.